menu
    • menu
    [{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Obinutuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Chugai Pharmaceutical \/ Nippon Shinyaku","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Nippon Shinyaku"}]

    Find Clinical Drug Pipeline Developments & Deals for Chlorambucil

    Menu

    Chlorambucil

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Chugai Pharmaceutical

                            Japan arrow
                            The Generic Rx Session
                            Not Confirmed

                            Chugai Pharmaceutical

                            Japan arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Obinutuzumab,Chlorambucil

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Nippon Shinyaku

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Humanized Anti-CD20 Monoclonal Antibody Gazyva Approved for Additional Indication of Chronic Lymphocytic Leuke...

                            Details : Gazyva (obinutuzumab), is a glycoengineered type II anti-CD20 monoclonal antibody designed to bind to CD20, a protein expressed on certain B cells, but not on stem cells or plasma cells.

                            Product Name : Gazyva

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 23, 2022

                            Lead Product(s) : Obinutuzumab,Chlorambucil

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Nippon Shinyaku

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth